Correlation between toxicity and dosimetric parameters for adjuvant intensity modulated radiation therapy of breast cancer: a prospective study

David Pasquier, Benoit Bataille, Florence Le Tinier, Raoudha Bennadji, Hélène Langin, Alexandre Escande, Emmanuelle Tresch, Franck Darloy, Damien Carlier, Frederik Crop, Eric Lartigau, David Pasquier, Benoit Bataille, Florence Le Tinier, Raoudha Bennadji, Hélène Langin, Alexandre Escande, Emmanuelle Tresch, Franck Darloy, Damien Carlier, Frederik Crop, Eric Lartigau

Abstract

Orcid: 0000-0001-6019-7309. In the treatment of breast cancer, intensity-modulated radiation therapy (IMRT) reportedly reduces the high-dose irradiation of at-risk organs and decreases the frequency of adverse events (AEs). Comparisons with conventional radiotherapy have shown that IMRT is associated with lower frequencies of acute and late-onset AEs. Here, we extended a prospective, observational, single-center study of the safety of IMRT to a second investigating center. Patients scheduled for adjuvant IMRT after partial or total mastectomy were given a dose of 50 Gy (25 fractions of 2 Gy over 5 weeks), with a simultaneous integrated boost in patients having undergone conservative surgery. 300 patients were included in the study, and 288 were analyzed. The median follow-up period was 2.1 years. The 2-year disease-free survival rate [95% CI] was 93.4% [89.2-96.0%]. Most AEs were mild. The most common AEs were skin-related-mainly radiodermatitis [in 266 patients (92.4%)] and hyperpigmentation (in 178 (61.8%)). 35% and 6% of the patients presented with grade 2 acute skin and esophageal toxicity, respectively. Only 4 patients presented with a grade 3 event (radiodermatitis). Smoking (odds ratio) [95% CI] = 2.10 [1.14-3.87]; p = 0.017), no prior chemotherapy (0.52 [0.27-0.98]; p = 0.044), and D98% for subclavicular skin (1.030 [1.001-1.061]; p = 0.045) were associated with grade ≥ 2 acute AEs. In a univariate analysis, the mean dose, (p < 0.0001), D2% (p < 0.0001), D50% (p = 0.037), D95% (p = 0.0005), D98% (p = 0.0007), V30Gy (p < 0.0001), and V45Gy (p = 0.0001) were significantly associated with grade ≥ 1 acute esophageal AEs. In a multivariate analysis, D95% for the skin (p < 0.001), D98% for the subclavicular skin and low D95% for the internal mammary lymph nodes were associated with grade ≥ 1 medium-term AEs. The safety profile of adjuvant IMRT after partial or total mastectomy is influenced by dosimetric parameters.

Trial registration: ClinicalTrials.gov NCT02281149.

Conflict of interest statement

The authors declare no competing interests.

Figures

Figure 1
Figure 1
The mean dose-volume histogram for the esophagus for patients without esophageal toxicity (black line) and patients with grade ≥ 1 acute esophageal adverse events (red line).

References

    1. Early Breast Cancer Trialists' Collaborative Group, et al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet. 378, 1707–1716 (2011).
    1. Early Breast Cancer Trialists' Collaborative Group, et al. Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: Meta-analysis of individual patient data for 8135 women in 22 randomised trials. Lancet383, 2127–2135 (2014).
    1. Riou O, Fenoglietto P, Lemanski C, Azria D. Intensity modulated radiotherapy for breast cancer. Cancer Radiother. 2012;16:479–484. doi: 10.1016/j.canrad.2012.05.010.
    1. Vicini FA, et al. Optimizing breast cancer treatment efficacy with intensity-modulated radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 2002;54:1336–1344. doi: 10.1016/S0360-3016(02)03746-X.
    1. Blom Goldman U, Svane G, Anderson M, Wennberg B, Lind P. Long-term functional and radiological pulmonary changes after radiation therapy for breast cancer. Acta Oncol. 2014;53:1373–1379. doi: 10.3109/0284186X.2014.934967.
    1. Chandra RA, et al. Radiation therapy risk factors for development of lymphedema in patients treated with regional lymph node irradiation for breast cancer. Int. J. Radiat. Oncol. Biol. Phys. 2015;91:760–764. doi: 10.1016/j.ijrobp.2014.12.029.
    1. Darby SC, et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N. Engl. J. Med. 2013;368:987–998. doi: 10.1056/NEJMoa1209825.
    1. Grantzau T, Overgaard J. Risk of second non-breast cancer among patients treated with and without postoperative radiotherapy for primary breast cancer: A systematic review and meta-analysis of population-based studies including 522,739 patients. Radiother. Oncol. 2016;121:402–413. doi: 10.1016/j.radonc.2016.08.017.
    1. Hidding JT, Beurskens CH, van der Wees PJ, van Laarhoven HW, Nijhuis-van der Sanden MW. Treatment related impairments in arm and shoulder in patients with breast cancer: A systematic review. PLoS ONE. 2014;9:e96748. doi: 10.1371/journal.pone.0096748.
    1. Korzets Y, Fyles A, Shepshelovich D, Amir E, Goldvaser H. Toxicity and clinical outcomes of partial breast irradiation compared to whole breast irradiation for early-stage breast cancer: A systematic review and meta-analysis. Breast Cancer Res. Treat. 2019;175:531–545. doi: 10.1007/s10549-019-05209-9.
    1. Barnett GC, et al. A randomised controlled trial of forward-planned radiotherapy (IMRT) for early breast cancer: Baseline characteristics and dosimetry results. Radiother. Oncol. 2009;92:34–41. doi: 10.1016/j.radonc.2009.03.003.
    1. Barnett GC, et al. Randomized controlled trial of forward-planned intensity modulated radiotherapy for early breast cancer: Interim results at 2 years. Int. J. Radiat. Oncol. Biol. Phys. 2012;82:715–723. doi: 10.1016/j.ijrobp.2010.10.068.
    1. Donovan E, et al. Randomised trial of standard 2D radiotherapy (RT) versus intensity modulated radiotherapy (IMRT) in patients prescribed breast radiotherapy. Radiother. Oncol. 2007;82:254–264. doi: 10.1016/j.radonc.2006.12.008.
    1. Mukesh MB, et al. Patient reported outcome measures (PROMs) following forward planned field-in field IMRT: Results from the Cambridge Breast IMRT trial. Radiother. Oncol. 2014;111:270–275. doi: 10.1016/j.radonc.2014.02.016.
    1. Pignol JP, et al. A multicenter randomized trial of breast intensity-modulated radiation therapy to reduce acute radiation dermatitis. J. Clin. Oncol. 2008;26:2085–2092. doi: 10.1200/JCO.2007.15.2488.
    1. Pasquier D, et al. Intensity-modulated radiation therapy with simultaneous integrated boost for locally advanced breast cancer: A prospective study on toxicity and quality of life. Sci. Rep. 2019;9:2759. doi: 10.1038/s41598-019-39469-8.
    1. Crop F, et al. Surface imaging, laser positioning or volumetric imaging for breast cancer with nodal involvement treated by helical TomoTherapy. J. Appl. Clin. Med. Phys. 2016;17:200–211. doi: 10.1120/jacmp.v17i5.6041.
    1. Hartford AC, et al. American College of Radiology (ACR) and American Society for Radiation Oncology (ASTRO) Practice Guideline for Intensity-modulated Radiation Therapy (IMRT) Am. J. Clin. Oncol. 2012;35:612–617. doi: 10.1097/COC.0b013e31826e0515.
    1. Offersen BV, et al. ESTRO consensus guideline on target volume delineation for elective radiation therapy of early stage breast cancer. Radiother. Oncol. 2015;114:3–10. doi: 10.1016/j.radonc.2014.11.030.
    1. Offersen BV, et al. ESTRO consensus guideline on target volume delineation for elective radiation therapy of early stage breast cancer, version 1.1. Radiother. Oncol. 2016;118:205–208. doi: 10.1016/j.radonc.2015.12.027.
    1. White, J. T. et al. Breast cancer atlas for radiation therapy planning: Consensus definitions. . Accessed 10 February 2020.
    1. National Cancer Institute Common Terminology Criteria for Adverse Events. . Accessed 10 February 2020.
    1. Fayers, P. M. et al. The EORTC QLQ-C30 Scoring Manual (3rd Edition). Published by: European Organisation for Research and Treatment of Cancer, Brussels 2001. .
    1. Fayers, P., Bottomley, A., Group EQoL., Quality of Life U. Quality of life research within the EORTC-the EORTC QLQ-C30. European Organisation for Research and Treatment of Cancer. Eur. J. Cancer. 38(Suppl 4), S125–S133 (2002).
    1. Wojcieszynski AP, Olson AK, Rong Y, Kimple RJ, Yadav P. Acute toxicity from breast cancer radiation using helical tomotherapy with a simultaneous integrated boost. Technol. Cancer Res. Treat. 2016;15:257–265. doi: 10.1177/1533034615574387.
    1. Freedman GM, et al. Intensity modulated radiation therapy (IMRT) decreases acute skin toxicity for women receiving radiation for breast cancer. Am. J. Clin. Oncol. 2006;29:66–70. doi: 10.1097/01.coc.0000197661.09628.03.
    1. Ekici K, et al. Is helical tomotherapy-based intensity-modulated radiotherapy feasible and effective in bilateral synchronous breast cancer? A two-center experience. J. BUON. 2016;21:46–52.
    1. Wang Q, Jie W, Liang Z, Wu H, Cheng J. Postmastectomy intensity modulation radiated therapy of chest wall and regional nodes: Retrospective analysis of the performance and complications up for 5 years. Medicine. 2017;96:e7956. doi: 10.1097/MD.0000000000007956.
    1. Aoulad N, et al. Acute toxicity of breast cancer irradiation with modulated intensity by tomotherapy((R)) Cancer Radiother. 2017;21:180–189. doi: 10.1016/j.canrad.2016.11.008.
    1. Caudrelier J, Meng J, Esche B, et al. IMRT sparing of normal tissues in locoregional treatment of breast cancer. Radiat. Oncol. 2014;9:161. doi: 10.1186/1748-717X-9-161.
    1. Harsolia A, et al. Intensity-modulated radiotherapy results in significant decrease in clinical toxicities compared with conventional wedge-based breast radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 2007;68:1375–1380. doi: 10.1016/j.ijrobp.2007.02.044.
    1. Lilla C, et al. Predictive factors for late normal tissue complications following radiotherapy for breast cancer. Breast Cancer Res. Treat. 2007;106:143–150. doi: 10.1007/s10549-006-9480-9.
    1. Keller LM, et al. Five-year results of whole breast intensity modulated radiation therapy for the treatment of early stage breast cancer: The Fox Chase Cancer Center experience. Int. J. Radiat. Oncol. Biol. Phys. 2012;84:881–887. doi: 10.1016/j.ijrobp.2012.01.069.
    1. Clarke M, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: An overview of the randomised trials. Lancet. 2005;366:2087–2106. doi: 10.1016/S0140-6736(05)67887-7.
    1. Bourgier C, et al. Late side-effects after curative intent radiotherapy: Identification of hypersensitive patients for personalized strategy. Crit. Rev. Oncol. Hematol. 2015;93:312–319. doi: 10.1016/j.critrevonc.2014.11.004.
    1. Straub JM, New J, Hamilton CD, Lominska C, Shnayder Y, Thomas SM. Radiation-induced fibrosis: mechanisms and implications for therapy. J. Cancer Res. Clin. Oncol. 2015;141:1985–1994. doi: 10.1007/s00432-015-1974-6.
    1. Back M, Guerrieri M, Wratten C, Steigler A. Impact of radiation therapy on acute toxicity in breast conservation therapy for early breast cancer. Clin. Oncol. 2004;16:12–16. doi: 10.1016/j.clon.2003.08.005.
    1. Blanchecotte J, Ruffier-Loubiere A, Reynaud-Bougnoux A, Barillot I. Acute skin toxicity in breast intensity modulated radiotherapy using field in field technique. Cancer Radiother. 2015;19:82–88. doi: 10.1016/j.canrad.2014.10.007.
    1. De Langhe S, et al. Factors modifying the risk for developing acute skin toxicity after whole-breast intensity modulated radiotherapy. BMC Cancer. 2014;14:711. doi: 10.1186/1471-2407-14-711.
    1. Franco P, et al. Intensity-modulated adjuvant whole breast radiation delivered with static angle tomotherapy (TomoDirect): A prospective case series. J. Cancer Res. Clin. Oncol. 2013;139:1927–1936. doi: 10.1007/s00432-013-1515-0.
    1. Shah C, Wobb J, Grills I, Wallace M, Mitchell C, Vicini FA. Use of intensity modulated radiation therapy to reduce acute and chronic toxicities of breast cancer patients treated with traditional and accelerated whole breast irradiation. Pract. Radiat. Oncol. 2012;2:e45–e51. doi: 10.1016/j.prro.2012.01.008.
    1. Fiorentino A, et al. Intensity modulated radiation therapy with simultaneous integrated boost in early breast cancer irradiation. Report of feasibility and preliminary toxicity. Cancer Radiother. 2015;19:289–294. doi: 10.1016/j.canrad.2015.02.013.
    1. Morganti AG, et al. Phase I-II studies on accelerated IMRT in breast carcinoma: Technical comparison and acute toxicity in 332 patients. Radiother. Oncol. 2009;90:86–92. doi: 10.1016/j.radonc.2008.10.017.
    1. Parekh A, et al. Predictors of radiation-induced acute skin toxicity in breast cancer at a single institution: Role of fractionation and treatment volume. Adv. Radiat. Oncol. 2018;3:8–15. doi: 10.1016/j.adro.2017.10.007.
    1. McDonald MW, Godette KD, Whitaker DJ, Davis LW, Johnstone PA. Three-year outcomes of breast intensity-modulated radiation therapy with simultaneous integrated boost. Int. J. Radiat. Oncol. Biol. Phys. 2010;77:523–530. doi: 10.1016/j.ijrobp.2009.05.042.
    1. Moody AM, et al. The influence of breast size on late radiation effects and association with radiotherapy dose inhomogeneity. Radiother. Oncol. 1994;33:106–112. doi: 10.1016/0167-8140(94)90063-9.
    1. Turesson I, Nyman J, Holmberg E, Oden A. Prognostic factors for acute and late skin reactions in radiotherapy patients. Int. J. Radiat. Oncol. Biol. Phys. 1996;36:1065–1075. doi: 10.1016/S0360-3016(96)00426-9.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi